Celyad - News

Corporate › Non-regulated January 13, 2020

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Corporate › Non-regulated December 10, 2019

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

Corporate › Non-regulated November 22, 2019

Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

Corporate › Non-regulated October 02, 2019

Celyad Announces October and November 2019 Investor Conference Schedule

Corporate › Non-regulated August 29, 2019

Celyad to Participate in Upcoming September 2019 Conferences

Corporate › Non-regulated August 16, 2019

Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call

Corporate › Non-regulated July 05, 2019

Celyad Presents Update on Autologous & Allogeneic NKG2D-based CAR-T Therapies in Solid Tumors

Corporate › Non-regulated July 02, 2019

Celyad to Host Conference Call to Review Clinical Update from ESMO 21st World GI Congress

Corporate › Non-regulated July 01, 2019

Celyad Announces Strategic Updates to the Autologous r/r AML and MDS Program

Corporate › Non-regulated May 29, 2019

Celyad to Participate in Upcoming June 2019 Conferences

Corporate › Non-regulated May 16, 2019

Celyad to Present Data at 24th Congress of the European Hematology Association

Corporate › Non-regulated May 02, 2019

Celyad Announces May 2019 Investor Conference Schedule